Purpose:To assess the central corneal thickness (CCT) and intraocular pressure (IOP) in premature and full-term newborns.Materials and Methods:In this study, we evaluated measurements of CCT and IOP in 45 premature and 45 full-term newborns. IOP was determined with topical anesthesia using a Tono-Pen AVIA, applanation tonometer and a wire lid retractor in premature newborns undergoing screening for retinopathy. Full-term newborns were used as a control group. CCT was determined with a portable pachymeter after IOP measurements had been made in both groups. Because there was high correlation of CCT and IOP between right and left eyes, only the right eye data were used for further analyses.Results:The mean gestational age was 31.5 ± 2.7 weeks (ranging 25-35 weeks) and the mean age at measurement after birth was respectively 36.3 ± 0.9 weeks (ranging 33-37 weeks) in premature newborns and 38.2 ± 0.7 weeks (ranging 38-41 weeks) and 42 ± 2.2 weeks (ranging 39-46 weeks) in full-term newborns. The mean IOP was 16.2 ± 2.7 mmHg (ranging 10-22 mmHg) in premature and 16.6 ± 2.3 mmHg (ranging 10-22 mmHg) in full-term newborns. The mean CCT was found 600 ± 50 μm (ranging 515-790 μm) in the premature group and 586 ± 48 μm (ranging 475-730 μm) in the full-term group. Mean CCT was greater in premature newborns than in full-term newborns, but the difference between groups was not statistically significant (P = 0.7). Mean IOP measurement in two groups was found very similar and the difference also was not statistically significant (P = 0.27). There was no correlation between IOP and CCT, gestational age, gestational weight, age at measurement, weight at measurement neither right nor left eye in both groups in multiple regression analysis.Conclusion:We found that premature infants have slightly thicker corneas but no high IOP measurements than full-term newborns. It could be concluded that in premature at the mean gestational age of 36 weeks CCT is not different from that of full-term newborns.
Background This study aimed to evaluate the factors influencing final visual acuity in pediatric traumatic cataracts. Methods Data of patients who presented with traumatic cataracts were reviewed retrospectively. We evaluated age at trauma; gender, trauma type, cause, and zone; duration between the time of trauma and cataract surgery; surgical method used; time, location, and type of intraocular lens (IOL) implantation; initial and final best corrected visual acuity (BCVA); amblyopia rate; and complications. Results In all, 61 eyes of 59 patients aged < 16 years with cataracts after trauma were included. The mean age of the children was 7.2 ± 3.9 years. Primary IOL implantation was performed in 70.9% of eyes. The BCVA was 0.7 LogMAR or better in 5.9% of the 49 eyes in which the visual acuity could be measured at the time of trauma and in 69.1% of 55 eyes in which it could be measured after treatment. Evaluation of factors potentially influencing the final visual acuity revealed that eyes that had undergone posterior capsulotomy (PC) and anterior vitrectomy (AV) during cataract surgery had significantly better final visual acuity compared with eyes that did not undergo these procedures. Conclusions In children with posttraumatic cataracts, final visual acuity was not affected by patient age and gender; trauma type, cause, and zone; duration between the time of trauma and cataract surgery; surgical method used; and time, location, and type of intraocular lens (IOL) implantation. Improvements in the final BCVA could be seen only by PC + AV combined with lens aspiration with or without IOL implantation. However, this approach of amblyopia treatment needs to be confirmed by more comprehensive and prospective studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.